[go: up one dir, main page]

PT3239177T - Novo anticorpo egfrviii e composição compreendendo o mesmo - Google Patents

Novo anticorpo egfrviii e composição compreendendo o mesmo

Info

Publication number
PT3239177T
PT3239177T PT149067126T PT14906712T PT3239177T PT 3239177 T PT3239177 T PT 3239177T PT 149067126 T PT149067126 T PT 149067126T PT 14906712 T PT14906712 T PT 14906712T PT 3239177 T PT3239177 T PT 3239177T
Authority
PT
Portugal
Prior art keywords
novel
composition
same
egfrviii antibody
egfrviii
Prior art date
Application number
PT149067126T
Other languages
English (en)
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of PT3239177T publication Critical patent/PT3239177T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT149067126T 2014-11-25 2014-11-25 Novo anticorpo egfrviii e composição compreendendo o mesmo PT3239177T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2014/011381 WO2016084993A1 (ko) 2014-11-25 2014-11-25 신규 EGFRvIII 항체 및 이를 포함하는 조성물

Publications (1)

Publication Number Publication Date
PT3239177T true PT3239177T (pt) 2021-05-14

Family

ID=56074535

Family Applications (1)

Application Number Title Priority Date Filing Date
PT149067126T PT3239177T (pt) 2014-11-25 2014-11-25 Novo anticorpo egfrviii e composição compreendendo o mesmo

Country Status (10)

Country Link
US (1) US10597457B2 (pt)
EP (1) EP3239177B1 (pt)
JP (1) JP6616833B2 (pt)
CN (1) CN107108735B (pt)
AU (1) AU2014412643B2 (pt)
CA (1) CA2968510C (pt)
DK (1) DK3239177T3 (pt)
ES (1) ES2871598T3 (pt)
PT (1) PT3239177T (pt)
WO (1) WO2016084993A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210032351A1 (en) * 2017-12-13 2021-02-04 Xdcexplorer (Shanghai) Co., Ltd. Egfrviii antibody and conjugate, and preparation method and use thereof
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
KR20240070579A (ko) * 2021-09-29 2024-05-21 내셔날 리서치 카운실 오브 캐나다 인간화 항-egfrviii 항체 및 이의 항원 결합 단편
CN114014928B (zh) * 2021-10-27 2023-05-12 南京安吉生物科技有限公司 抗hmmw抗体、包含该抗体的组合物、编码该抗体的核酸分子及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4620808B2 (ja) * 1994-11-28 2011-01-26 トーマス・ジェファーソン・ユニバーシティ 突然変異上皮成長因子受容体を標的とする試薬および方法
EP1266009B1 (en) 2000-02-25 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
AU2003215381A1 (en) * 2002-02-25 2003-09-09 Georgetown University EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
EP3037105B1 (en) 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
US9249217B2 (en) * 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
WO2012139106A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus
US20140314667A1 (en) * 2011-11-16 2014-10-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2015018527A1 (en) * 2013-08-07 2015-02-12 Affimed Therapeutics Ag ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Also Published As

Publication number Publication date
JP6616833B2 (ja) 2019-12-04
WO2016084993A1 (ko) 2016-06-02
CA2968510C (en) 2020-11-03
AU2014412643A1 (en) 2017-06-15
EP3239177A1 (en) 2017-11-01
JP2018501783A (ja) 2018-01-25
DK3239177T3 (da) 2021-04-26
CA2968510A1 (en) 2016-06-02
CN107108735A (zh) 2017-08-29
ES2871598T3 (es) 2021-10-29
EP3239177A4 (en) 2018-05-02
US10597457B2 (en) 2020-03-24
CN107108735B (zh) 2021-05-04
EP3239177B1 (en) 2021-03-17
AU2014412643B2 (en) 2018-08-30
US20170327585A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
IL265844A (en) Anti-lag-3 antibodies and preparations
IL262176A (en) Anti-tim-3 antibodies and preparations
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
ZA201701168B (en) Antibodies, compositions, and uses
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
IL254517B (en) Antibodies against muc16 and their uses
IL252804B (en) Anti-c10orf54 antibodies and their use
IL251248A0 (en) Anti-interleukin-33 antibodies and their uses
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
IL254955A0 (en) Anti-pacap antibodies and their uses
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
PT3239177T (pt) Novo anticorpo egfrviii e composição compreendendo o mesmo